Patricia Inácio, PhD, science writer —

The Leukemia & Lymphoma Society (LLS) is once again running its Scenic Shore Bike Tour to raise awareness and support for people with blood cancers, including myeloma. Going on its 32nd edition and set to start July 27 in Mequon, Wisconsin, the annual Scenic Shore Bike Tour…

Pfizer’s Elrexfio (elranatamab) extends the lives of adults with relapsed or refractory multiple myeloma (RRMM) who received at least two prior lines of therapy and whose cancer has worsened since their last treatment. Median overall survival was 24.6 months, or more than two years, according to data from the 123 RRMM…

Once-weekly induction therapy with bortezomib is as efficient as the standard two times a week dosing in people newly diagnosed with multiple myeloma, a large retrospective real-world study suggests. No differences were seen between both regimens regarding survival overall and the time patients lived without disease progression, but the…

Johnson & Johnson has applied to the European Medicines Agency (EMA) for approval of its under-the-skin formulation of Darzalex (daratumumab), called Darzalex Faspro (daratumumab and hyaluronidase-fihj), in combination with a standard triple-therapy regimen for treating adults with newly diagnosed multiple myeloma who are eligible for…

GlaxoSmithKline (GSK)’s Blenrep (belantamab mafodotin) significantly reduced by more than half the risk of disease progression or death in people with relapsed or refractory multiple myeloma (RRMM) relative to Darzalex (daratumumab). A nearly three times greater delay in disease progression and a 43% lower risk of death was associated…

Obesity, a history of heavy smoking, and limited sleep are risk factors for developing monoclonal gammopathy of undetermined significance (MGUS), a precursor condition to multiple myeloma, a large U.S. study shows. These findings will help inform future work to identify groups who “may benefit from targeted screening strategies, enhanced…

STAR-LLD, a continuous infusion of low-dose lenalidomide into the blood, shows the potential to be a better treatment choice than Revlimid, an oral formulation of lenalidomide, for certain people with multiple myeloma, its developer, Starton Therapeutics, reports. The company’s announcement was based on early data from a…

When added to a second-line combination therapy, Blenrep (belantamab mafodotin) — developed by GlaxoSmithKline (GSK) for relapsed or treatment-resistant multiple myeloma — works better than Darzalex (daratumumab) at significantly delaying disease progression or death among…

Safety and response rates with Abecma (idecabtagene vicleucel) were seen to vary with race in people with relapsed or refractory multiple myeloma (RRMM), but overall survival rates were similar between hard-to-treat Black, Hispanic, and white patients, a new U.S. study found. “We see that Black and white patients with multiple…

A gene therapy designed by Kelonia Therapeutics to work as an off-the-shelf or readily available CAR T-cell therapy for multiple myeloma showed early signs of safety and efficacy in mouse models of the disease and in non-human primates. Specifically, in a mouse model, CAR T-cells generated in vivo,…